Aclaris Therapeutics, Inc.ACRSNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank25
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-823.78%
↑ 14% vs avg
Percentile
P25
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-954.59%
Historical baseline
PeriodValueYoY Change
2025-823.78%-198.2%
2024-276.28%+25.2%
2023-369.46%-30.3%
2022-283.53%+70.3%
2021-953.42%-30.9%
2020-728.09%+65.9%
2019-2134.71%-166.7%
2018-800.53%+74.8%
2017-3176.05%-
20160.00%-